glp-1/gcgr dual agonist Design of novel Xenopus GLP-1-based glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists Design of a highly potent
Description
In 2013, the group around Shimasaki was the first reporting that des-fluoro-sitagliptin attenuated body adiposity, without affecting food intake, in C57BL/6 mice with diet-induced obesity (128)
Another way in which DPP-4 inhibitors may affect bone metabolism is through a pathway linked to 25(OH)-D levels (Vitamin D, [136])
In 1980, the intestinal glucagon-like material, glicentin, was identified along with a smaller species named oxyntomodulin in 1982
For patients at low cardiovascular risk, metformin remains a trusted and effective option
PubChem CID: 16134704
Problem or solution: the strange story of glucagon
